Whole-body distribution and radiation dosimetry of 11c-elacridar and 11C-tariquidar in humans

Journal of Nuclear Medicine

Volumn 57, Issue 8, 2016, Pages 1265-1268

  Bauer, Martin ^a   Blaickner, Matthias ^a,b   Philippe, Cecile ^a   Wadsak, Wolfgang ^a   Hacker, Marcus ^a   Zeitlinger, Markus ^a   Langer, Oliver ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b AIT AUSTRIAN INSTITUTE OF TECHNOLOGY   (Austria)

Author keywords

11C elacridar; 11C tariquidar; Breast cancer resistance protein; P glycoprotein; Radiation dosimetry

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; ELACRIDAR C 11; MULTIDRUG RESISTANCE PROTEIN 1; RADIOPHARMACEUTICAL AGENT; TARIQUIDAR C 11; UNCLASSIFIED DRUG; ACRIDINE DERIVATIVE; CARBON; ELACRIDAR; QUINOLINE DERIVATIVE; TARIQUIDAR; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADULT; ARTICLE; BLADDER; BONE MARROW; BRAIN; CARDIAC MUSCLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; DRUG EXCRETION; FEMALE; GALLBLADDER; HUMAN; IMAGE ANALYSIS; KIDNEY; LIVER; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; QUADRICEPS FEMORIS MUSCLE; RADIATION DOSE DISTRIBUTION; RADIOLOGICAL PARAMETERS; SMALL INTESTINE; SPLEEN; STANDARD UPTAKE VALUE; URINARY EXCRETION; WHOLE BODY PET; ANTIBODY SPECIFICITY; CLINICAL TRIAL; METABOLIC CLEARANCE RATE; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; RADIATION DOSE; TISSUE DISTRIBUTION; WHOLE BODY COUNTING;

ACRIDINES; ADULT; CARBON RADIOISOTOPES; HUMANS; METABOLIC CLEARANCE RATE; ORGAN SPECIFICITY; POSITRON-EMISSION TOMOGRAPHY; QUINOLINES; RADIATION DOSAGE; RADIOPHARMACEUTICALS; TETRAHYDROISOQUINOLINES; TISSUE DISTRIBUTION; WHOLE-BODY COUNTING;

EID: 84982797704     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.116.175182     Document Type: Article

References (17)

1. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215-236.
2. Agarwal S, Hartz AM, Elmquist WF, Bauer B. Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des. 2011;17:2793-2802.
3. Wanek T, Mairinger S, Langer O. Radioligands targeting P-glycoprotein and other drug efflux proteins at the blood-brain barrier. J Labelled Comp Radio-pharm. 2013;56:68-77.
4. Wanek T, Kuntner C, Bankstahl JP, et al. A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32:2002-2011.
5. Bankstahl JP, Bankstahl M, Römermann K, et al. Tariquidar and elacridar are dose-dependently transported by p-glycoprotein and bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study. Drug Metab Dispos. 2013;41:754-762.
6. 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier. J Nucl Med. 2013;54:1181-1187.
7. Bauer M, Römermann K, Karch R, et al. A pilot PET study to assess the functional interplay between ABCB1 and ABCG2 at the human blood-brain barrier. Clin Pharmacol Ther. March 3, 2016 [Epub ahead of print].
8. Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature. J Nucl Med. 2009;50:477-484.
9. Coffey JL, Cristy M, Warner GG. Specific absorbed fractions for photon sources uniformly distributed in the heart chambers and heart wall of a heterogeneous phantom. J Nucl Med. 1981;22:65-71.
10. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
11. The 2007 Recommendations of the International Commission on Radiological Protection: ICRP publication 103. Ann ICRP. 2007;37:1-332.
12. de Bruin M, Miyake K, Litman T, Robey R, Bates SE. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett. 1999;146:117-126.
13. Kannan P, Telu S, Shukla S, et al. The "specific" P-glycoprotein inhibitor tar-iquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci. 2011;2:82-89.
14. 11C]XR9576 to assess the function of drug efflux transporters using PET. Ann Nucl Med. 2010;24:403-412.
15. 11C]GF120918 by PET in mice. Mol Imaging Biol. 2011;13:152-160.
16. Kannan P, Brimacombe KR, Kreisl WC, et al. Lysosomal trapping of a radiola-beled substrate of P-glycoprotein as a mechanism for signal amplification in PET. Proc Natl Acad Sci USA. 2011;108:2593-2598.
17. van der Aart J, Hallett WA, Rabiner EA, Passchier J, Comley RA. Radiation dose estimates for carbon-11-labelled PET tracers. Nucl Med Biol. 2012;39:305-314.